The original success of the copyright undeniably reshaped the drug landscape, but placing funds in companies strongly reliant on generic versions presents a uncertain picture. While early earnings were impressive, the expiration of patents and the appearance of less expensive alternatives have diminished the customer base. Therefore, a thorough ass